Items Tagged with 'Boston Scientific FDA'
BSX Reports Net Sales of $1.828 Billion
On July 26, 2012, Boston Scientific Corporation (NYSE: BSX) released financial results for the second quarter ended on June 30, 2012.
BSX Acquires Cameron Health for $150 Million
On June 8, 2012, Boston Scientific Corporation (NYSE: BSX) closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its product portfolio the world's first and only commercially available subcutaneous implantable cardioverter defibrillator, called the S-ICD® System.
BSX Receives FDA Approval
On June 4, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System.
BSX Recieves FDA Pacemaker Approval
On May 7, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™ cardiac resynchronization therapy pacemakers (CRT-P).
On February 22, 2012, Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack.
On December 8, 2011, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous Lead for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.
On November 30, 2011, Boston Scientific Corporation (NYSE: BSX) announced FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators to treat heart failure and sudden cardiac death.
Your Financial Security is Serious Business...
so why should you trust The Turnaround Letter?
Ranked Among Top-2 for 15-Yr. Returns: Turnaround Letter's 12.1% vs. S&P's 2.5%
28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
Diverse Monthly Stock Picks Personally Selected by George Putnam
Distressed Investing Blog
Most investors remember the severity of the 2009 market nosedive: The Dow's final closing price on March 9, 2009 was just 6,547.05, and the S&P 500 dropped to just 676.53. Looking back now with six years of hindsight under our belt, we recently took a look at some of the stocks that have significantly lagged over the six-year period since the March 9, 2009 low point for some unique value stock opportunities.
George Putnam has always followed the same straight-forward and highly-profitable investment philosophy. He published his first Turnaround Letter issue back in 1986, and readers have seen extraordinary long-term stock profit ever since.
In fact, 12 of 2014's 13 closed-out purchase recommendations saw gains--with five of those enjoying total returns greater than 100%. The Turnaround Letter's average return for 2014's stock picks is +82%:
2014 Closed Out Purchase Recommendations
* Calculation includes dividends and price changes between purchase recommendation and current price.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.